MA44286A - Formulation pharmaceutique de cinéol et d'amoxicilline - Google Patents
Formulation pharmaceutique de cinéol et d'amoxicillineInfo
- Publication number
- MA44286A MA44286A MA044286A MA44286A MA44286A MA 44286 A MA44286 A MA 44286A MA 044286 A MA044286 A MA 044286A MA 44286 A MA44286 A MA 44286A MA 44286 A MA44286 A MA 44286A
- Authority
- MA
- Morocco
- Prior art keywords
- cineol
- amoxicillin
- pharmaceutical formulation
- formulation
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1655017A FR3052066B1 (fr) | 2016-06-02 | 2016-06-02 | Formulation pharmaceutique de cineol et d'amoxicilline |
| FR1655018A FR3052065B1 (fr) | 2016-06-02 | 2016-06-02 | Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne |
| MA39084A MA39084A1 (fr) | 2016-06-02 | 2016-06-02 | Formulation pharmaceutique de cineol et d'amoxicilline |
| MA39085A MA39085B1 (fr) | 2016-06-02 | 2016-06-02 | Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44286A true MA44286A (fr) | 2019-01-09 |
Family
ID=59399462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044286A MA44286A (fr) | 2016-06-02 | 2017-06-02 | Formulation pharmaceutique de cinéol et d'amoxicilline |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11872216B2 (enExample) |
| EP (1) | EP3463479B1 (enExample) |
| JP (1) | JP7033586B2 (enExample) |
| CN (1) | CN109562182A (enExample) |
| CA (1) | CA3026323A1 (enExample) |
| MA (1) | MA44286A (enExample) |
| SA (1) | SA518400554B1 (enExample) |
| WO (1) | WO2017209588A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017209588A2 (fr) * | 2016-06-02 | 2017-12-07 | Advanced Scientific Developements | Formulation pharmaceutique de cinéol et d'amoxicilline |
| ES2986948T3 (es) | 2019-12-04 | 2024-11-13 | Pranarom Int S A | Procedimiento de transformación de un aceite esencial |
| DE102021132055B4 (de) | 2021-10-08 | 2024-12-12 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mit beschränkter Haftung | Neue Therapiekonzepte für die Behandlung von Otitis |
| CN118267361B (zh) * | 2024-05-31 | 2024-08-23 | 潍坊格润药业有限公司 | 一种兽用复方阿莫西林可溶性粉 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102319409A (zh) * | 2003-07-17 | 2012-01-18 | 纽约市哥伦比亚大学托管会 | 含有季铵化合物及精油和/或精油成分的协同组合的抗微生物组合物 |
| WO2006120496A1 (fr) | 2005-05-13 | 2006-11-16 | Advanced Scientific Developements | Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l’ eugenol, le thymol, le borneol, et le carvacrol |
| WO2006120494A1 (fr) | 2005-05-13 | 2006-11-16 | Advanced Scientific Developements | Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l’eugenol, le borneol et les carvacrol |
| WO2006120495A1 (fr) | 2005-05-13 | 2006-11-16 | Advanced Scientific Developements | Composition pharmaceutique comprenant un antiviral, an antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol, le thymol, l’eugenol, le borneol et le carvacrol |
| US20080139526A1 (en) * | 2006-12-06 | 2008-06-12 | Donald Treacy | Modified release dosage forms of amoxicillin |
| DE102006007830A1 (de) * | 2006-02-17 | 2007-08-30 | Grünenthal GmbH | Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure |
| US20110136883A1 (en) * | 2008-04-09 | 2011-06-09 | Lek Pharmaceuticals D.D. | Granulation of active pharmaceutical ingredients |
| FR2937549B1 (fr) | 2008-10-29 | 2011-04-01 | Centre Nat Rech Scient | Nanoparticules de derives beta-lactamine |
| US20130324597A1 (en) * | 2010-12-09 | 2013-12-05 | Septeos | Pharmaceutical composition comprising trans-cinnamaldehyde and its use in the treatment of infections |
| JP2014507441A (ja) | 2011-02-25 | 2014-03-27 | エイド・ファルマ | 単独で、または抗生物質と共に感染症を予防または治療するための精油のナノカプセル化 |
| NZ707855A (en) | 2012-11-06 | 2018-11-30 | Rochal Ind Llc | Delivery of biologically-active agents using volatile, hydrophobic solvents |
| MA35295B1 (fr) | 2012-12-31 | 2014-08-01 | Advanced Scient Developments | Complexe moleculaire detoxifiant et antimicrobien |
| FR3025719A1 (fr) * | 2014-09-15 | 2016-03-18 | Septeos | Antimicrobiens potentialises |
| WO2017209588A2 (fr) * | 2016-06-02 | 2017-12-07 | Advanced Scientific Developements | Formulation pharmaceutique de cinéol et d'amoxicilline |
-
2017
- 2017-06-02 WO PCT/MA2017/000014 patent/WO2017209588A2/fr not_active Ceased
- 2017-06-02 EP EP17743405.7A patent/EP3463479B1/fr active Active
- 2017-06-02 CA CA3026323A patent/CA3026323A1/fr active Pending
- 2017-06-02 US US16/306,262 patent/US11872216B2/en active Active
- 2017-06-02 JP JP2019515760A patent/JP7033586B2/ja active Active
- 2017-06-02 MA MA044286A patent/MA44286A/fr unknown
- 2017-06-02 CN CN201780041549.7A patent/CN109562182A/zh active Pending
-
2018
- 2018-11-29 SA SA518400554A patent/SA518400554B1/ar unknown
-
2024
- 2024-01-10 US US18/408,636 patent/US20240148702A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109562182A (zh) | 2019-04-02 |
| US11872216B2 (en) | 2024-01-16 |
| SA518400554B1 (ar) | 2024-07-29 |
| US20190255024A1 (en) | 2019-08-22 |
| BR112018074913A2 (pt) | 2019-03-12 |
| WO2017209588A3 (fr) | 2018-03-15 |
| WO2017209588A2 (fr) | 2017-12-07 |
| CA3026323A1 (fr) | 2017-12-07 |
| US20240148702A1 (en) | 2024-05-09 |
| EP3463479B1 (fr) | 2026-04-15 |
| JP2019521178A (ja) | 2019-07-25 |
| JP7033586B2 (ja) | 2022-03-10 |
| EP3463479A2 (fr) | 2019-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3548000A4 (en) | PHARMACEUTICAL COMPOSITIONS OF ATROPINE | |
| MA43709A (fr) | Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations | |
| PL3717471T3 (pl) | Nowe związki i zawierające je kompozycje farmaceutyczne do leczenia chorób | |
| EP3516627A4 (en) | AVATAR CREATION AND EDITING | |
| MA46466A (fr) | Formulations pharmaceutiques de protéines à viscosité réduite | |
| EP3603620A4 (en) | LIPOSOME COMPOSITION AND PHARMACEUTICAL COMPOSITION | |
| EP3402549A4 (en) | MICRONADELE COMPOSITIONS AND METHOD FOR USE THEREOF | |
| EP3355954A4 (en) | RELEASE PROCEDURE AND COMPOSITIONS | |
| EP3474844A4 (en) | PHARMACEUTICAL FOR EVAPORATING AND SMOKING | |
| EP3700504A4 (en) | TOPICAL PHARMACEUTICAL COMPOSITION OF ADAPALEN AND MINOCYCLINE | |
| EP3638205A4 (en) | DEVICES AND METHODS FOR ADMINISTERING THERAPEUTICS | |
| MA44391A (fr) | Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20 | |
| EP3412660A4 (en) | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREWITH | |
| FR3032353B1 (fr) | Composition pharmaceutique et dispositif pour le traitement de la douleur | |
| MA43705A (fr) | Formulation pharmaceutique | |
| EP3505161A4 (en) | SUBLINGUAL PHARMACEUTICAL COMPOSITION OF EDARAVON AND (+) - 2-BORNEOL | |
| EP3409660A4 (en) | CYCLOAMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | |
| EP3777866A4 (en) | PHARMACEUTICAL COMPOSITION AND ADMINISTRATION THEREOF | |
| MA44862A (fr) | Formulations de fulvestrant et méthodes d'utilisation de celles-ci | |
| MA53333A (fr) | Formulations pharmaceutiques d'anticorps masqués | |
| EP3556771A4 (en) | CLAUDIN-5 ANTIBODIES AND MEDICINAL PRODUCTS THEREOF | |
| EP3542821A4 (en) | P53 DEGRADATION INDUCTING MOLECULE AND PHARMACEUTICAL COMPOSITION | |
| MA52587A (fr) | Composés d'azabenzimidazole et produit pharmaceutique | |
| EP3373907A4 (en) | RETARD PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | |
| MA53466A (fr) | Formulation stable d'anticorps anti-osmr |